Johnson & Johnson rushes vaccines to market through their EUA status as they partner with the U.S. government and medical centers worldwide. Funds allocated by their associates exceed $1 billion in research, development, and clinical trials on human subjects as they skip animal trials.
Their primary emphasis is minority populations for experiments. They claim the pathogen attacks colored groups at different rates. Therefore, they prime their target’s immune system with a common cold type of strain, the adenovirus. Throughout the process, the subjects don’t understand the consequences of what happens once they encounter a wild variation of the virus.
But to Big Pharma, it doesn’t matter. Johnson & Johnson looks to release over a billion vaccines by 2021, with an unspecified amount thereafter.
Hallie Levine. 2021. “COVID-19 Update: Your Latest Questions About Johnson & Johnson’s Investigational Vaccine Candidate Answered.” Content Lab U.S. January 5, 2021.